Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-label, Observational Study of Telbivudine Treatment Outcome in Patients With Chronic B Virus Infection

NCT01958229 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT01958229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01958229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-label, Observational Study of Telbivudine Treatment Outcome in Patients With Chronic B Virus Infection
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Completed
Start date
December 31, 2009
Completion date
April 30, 2013
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

24-week pcr negativity of telbivudine, chronic hepatitis b, hbeag seroconversion rate at 52 and 104 week, pcr negativity at 52 and 104 week, roadmap concept in chronic hepatitis b treatment